A Phase 1b Study of Bulumtatug Fuvedotin in People With Triple-Negative Breast Cancer

Full Title

An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BF, 9MW2821) in Subjects with Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated with Antibody-Drug Conjugates

Purpose

Researchers want to see if bulumtatug fuvedotin works well against breast cancer. The people in this study have triple-negative breast cancer (TNBC) that came back or spread after treatment. 

TNBC is not fueled by estrogen or progesterone and does not have the HER2 protein. As a result, it cannot be treated with medications that target those proteins.

Bulumtatug fuvedotin is an antibody-drug conjugate (ADC). ADCs are made of an antibody linked to an anti-cancer drug. The antibody part binds to certain proteins on cancer cells. The linked drug then enters these cells and kills them, with a reduced risk of harming other cells. Bulumtatug fuvedotin is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Nour Abuhadra’s office at 646-888-4451.